Breast cancer (BC) poses a significant worldwide health challenge. In
the year 2020, more than 2.3 million cases were detected, and there
were approximately 685,000 deaths attributed to BC [1]. Although
systemic treatments are gaining importance in BC management, surgery
continues to be the fundamental treatment approach for the majority of
early-stage patients. A prolonged discussion continues, examining the
overall survival rates between mastectomy and breast-conserving therapy
(BCT), yielding inconclusive results. Nevertheless,
breast-conservative therapy appears to present fewer complications [2,
3]. Patients undergoing BCT experience enhanced cosmetic results and a
better quality of life compared to those opting for non-reconstructed
mastectomy
